1. Lally, J., MacCabe, J.H.: Personalised approaches to pharmacotherapy for schizophrenia. Adv. Psychiatric Treat. 22(2), 78–86 (2016). (Date of Publication: March 2016.;2016)
2. National Collaborating Centre for Mental Health. Psychosis and schizophrenia in adults. NICE guideline (CG178). 2014
3. Wimberley, T., MacCabe, J.H., Laursen, T.M., Sorensen, H.J., Astrup, A., Horsdal, H.T., et al.: Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. Am. J. Psychiatry 174(10), 990–998 (2017).
https://doi.org/10.1176/appi.ajp.2017.16091097
4. Galletly, C., Castle, D., Dark, F., Humberstone, V., Jablensky, A., Killackey, E., et al.: Royal Australian and New Zealand college of psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust. N. Z. J. Psychiatry 50(5), 410–472 (2016).
https://doi.org/10.1177/0004867416641195
5. Loosbrock, D.L., Zhao, Z., Johnstone, B.M., Morris, L.S.: Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia. J. Ment. Health Policy Econ. 6(2), 67–75 (2003)